Concepedia

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Brendan C. Bender, Franziska Schaedeli‐Stark, R Koch, Amita Joshi, Yu‐Waye Chu, Hope S. Rugo, Ian E. Krop, Sandhya Girish, Lena E. Friberg, Manish Gupta

Cancer Chemotherapy and Pharmacology · 2012 · 88 citations · 22 references

DOI

Concepts

References

22

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.7K citations

, , +17

The Chemotherapy Source Book

Annals of Internal Medicine · 1992 · 793 citations

, , +17

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

, , +17

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

, , +17

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Lena E. Friberg, Anja Henningsson, Hugo Maas et al. · Journal of Clinical Oncology · 2002 · 528 citations

, , +17